Navigation Links
20-City Zagat Survey(R) Guide Spotlights Outdoor Destinations and Offers Allergy Management Tips
Date:3/11/2008

"Out & About with Allergies" Guide Now Available in Time for Spring Allergy

Season

RESEARCH TRIANGLE PARK, N.C., March 11 /PRNewswire-FirstCall/ -- A special-edition Zagat Survey(R) guide, launched today, offers people with seasonal and year-round allergies an insider's view of the most exciting outdoor destinations in 20 US cities -- and tips on how to manage their allergy symptoms so they can enjoy being outside. The free guide is available at http://www.outandaboutwithallergies.com.

Zagat Survey(R), the leading publisher of consumer-based leisure content, and GlaxoSmithKline, maker of the allergy medication Veramyst(TM) (fluticasone furoate) Nasal Spray, created Out & About with Allergies: An Insider's Guide to Enjoying the City. Actor and allergy sufferer James Denton of Desperate Housewives is helping introduce the guide in order to bring attention to seasonal allergies and to encourage other allergy sufferers to manage their symptoms so that they can better enjoy outdoor experiences.

"I suffer with seasonal allergies, so I know how important it is to manage my symptoms," Denton said. "And for people like me who love the outdoors, this special-edition Zagat Guide introduces new places you can really enjoy when your allergy symptoms are under control."

The guide covers chic restaurants with outdoor dining and rooftop bars as well as secluded gardens and walking paths in Atlanta, Boston, Chicago, Cincinnati, Dallas/Ft. Worth, Denver, Houston, Las Vegas, Los Angeles, Miami, New Orleans, New York, Orlando/Tampa, Philadelphia, Phoenix/Scottsdale, Salt Lake City, San Diego, San Francisco, Seattle and Washington, DC. Out & About with Allergies also features useful tips for managing seasonal and year-round allergy symptoms.

"People with allergies may feel miserable, particularly if they experience multiple symptoms that persist
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. WellPoint Taps Zagat Survey to Help Consumers Rate Experiences with Their Doctors
2. FDA Updates Prescription Guidelines for Blood Thinner
3. New Asthma Guidelines Stress Disease Control
4. Study finds primary care depression treatment often does not follow quality guidelines
5. Microarray provides 3 genomic guides to breast cancer treatment decisions
6. New lung cancer guidelines oppose general CT screening
7. New Lung Cancer Guidelines Oppose General CT Screening
8. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
9. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
10. Long-awaited international ethical guidelines for biobank researchers
11. Internal medicine physicians recommend key elements to guide state initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 1The American Legion Calls for Revamping and Expansion of Veterans and Military Health Care 55198 2New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 1New Study of House Health Reform Bill 3A California Faces Over 243 7 Billion in Medicare Funded Nursing Home Cuts Over Ten Years 55196 2Testosterone Therapy May Help Men With Heart Failure 55194 1Testosterone Therapy May Help Men With Heart Failure 55194 2Testosterone Therapy May Help Men With Heart Failure 55194 3